Stifel Financial
HRTX icon

Stifel Financial’s Heron Therapeutics HRTX Stock Holding History

Stifel Financial’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-15,081
Closed -$41.8K – 3408
2024
Q1 		$41.8K Sell
15,081
-10,707
-42% -$26.9K ﹤0.01% 3268
2023
Q4 		$43.8K Sell
25,788
-7,425
-22% -$8.18K ﹤0.01% 3232
2023
Q3 		$34.2K Buy
33,213
+150
+0.5% +$213 ﹤0.01% 3210
2023
Q2 		$38.4K Sell
33,063
-1,596
-5% -$2.85K ﹤0.01% 3253
2023
Q1 		$52.3K Sell
34,659
-1,222
-3% -$3.06K ﹤0.01% 3231
2022
Q4 		$89.7K Sell
35,881
-11,298
-24% -$36.4K ﹤0.01% 3147
2022
Q3 		$199K Sell
47,179
-428
-0.9% -$1.68K ﹤0.01% 2958
2022
Q2 		$133K Sell
47,607
-1,720
-3% -$6.91K ﹤0.01% 3109
2022
Q1 		$282K Sell
49,327
-2,711
-5% -$19.8K ﹤0.01% 2907
2021
Q4 		$475K Sell
52,038
-11,822
-19% -$121K ﹤0.01% 2616
2021
Q3 		$683K Sell
63,860
-25,506
-29% -$311K ﹤0.01% 2380
2021
Q2 		$1.39M Buy
89,366
+2,241
+3% +$35.7K ﹤0.01% 1857
2021
Q1 		$1.41M Buy
87,125
+13,166
+18% +$235K ﹤0.01% 1751
2020
Q4 		$1.56M Sell
73,959
-5,909
-7% -$103K ﹤0.01% 1539
2020
Q3 		$1.18M Buy
79,868
+407
+0.5% +$6.35K ﹤0.01% 1519
2020
Q2 		$1.17M Sell
79,461
-65,274
-45% -$1.07M ﹤0.01% 1450
2020
Q1 		$1.69M Buy
144,735
+14,745
+11% +$277K ﹤0.01% 1130
2019
Q4 		$3.04M Buy
129,990
+20,670
+19% +$457K 0.01% 1095
2019
Q3 		$2.04M Buy
109,320
+859
+0.8% +$15.8K 0.01% 1302
2019
Q2 		$2.03M Buy
108,461
+51,658
+91% +$1.03M 0.01% 1324
2019
Q1 		$1.37M Buy
+56,803
New +$1.49M ﹤0.01% 1470
2018
Q3 		– Sell
-28,134
Closed -$1.09M – 2785
2018
Q2 		$1.09M Buy
+28,134
New +$896K ﹤0.01% 1554

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Stifel Financial's HRTX Position: Q2 2024 in Review

Stifel Financial sold out of Heron Therapeutics (HRTX) in Q2 2024, closing a stake of 15,081 shares — an estimated $41.8K sold.

Stifel Financial first reported a position in HRTX in Q2 2018 and held it in 22 quarters. The position peaked at $3.04M in Q4 2019. 190 funds tracked by Wall St. Rank hold HRTX as of Q2 2024.

  • Stifel Financial reported no remaining Heron Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Stifel Financial sold 15,081 Heron Therapeutics shares in Q2 2024, an estimated $41.8K.
  • Stifel Financial first reported a position in Heron Therapeutics in Q2 2018 and held it in 22 quarters.
  • Stifel Financial's Heron Therapeutics position peaked at $3.04M in Q4 2019.
  • 190 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2024.

Based on Stifel Financial's 13F filing for Q2 2024, filed 13 Aug 2024.